肿瘤靶向性复制溶瘤病毒治疗肿瘤的潜能和挑战OA

The clinical benefits of tumor immunotherapy are still limited by non-responses or resistance of cancer patients.Tumor-targeted replicating oncolytic viruses(TOV)can act as"initiators"and"catalysts"for immunotherapy,converting"cold"tumors into"hot"tumors,with controllable safety and good tolerance.This article systematically reviews the mechanism,clinical progress,and key challenges of TOV and possible solutions to overcome the challenges,focusing on discussing the impact of the host immune system on TOV,the development of more effective TOV platforms,strategies for efficient intravenous administration of TOV,the choice of preclinical animal evaluation models with better clinical predictive value,the optimization of treatment scheduling of combination therapy and directions for future development.This review discusses the potential of TOV as a pivotal synergistic and catalytic platform in cancer immunotherapy,proposing novel strategies to enhance immune responses and achieve long-term efficacy against solid tumors.